VIB scientists connected to the Katholieke Universiteit Leuven, in collaboration with the Flemish biotech company ThromboGenics, have been studying the anti-cancer action of anti-PLGF.
This substance appears not only to be successful in the treatment of tumors for which the current therapies fail, but it also contributes to the greater effectiveness of existing chemotherapy, and still without side effects. Thus, anti-PLGF might possibly form the basis for a new treatment for cancer. This new finding, which is extremely important, was published in one of the most prestigious journals: CELL.
What is cancer?
Our body is built of billions of cells. Old or damaged cells are continuously being replaced, and cell division is strictly controlled, with new cells produced only as they are needed. However, this is not the case with cancer cells: cancer cells know how to circumvent the control system and go on multiplying out of control. The proliferating cells spread to surrounding tissue or are carried to other tissues and organs via the blood or the lymph system. This seriously disrupts our body’s vital functions - often with deadly consequences.
Blood vessel formation (or angiogenesis)
Every developing tissue is supplied with oxygen and nutrients via our blood vessels. But tumors grow much more quickly than normal tissues and so they have a greater need of nutrients. This is why, at a certain moment, tumor cells produce growth factors. These growth factors stimulate the formation of blood vessels that feed the tumor cells. In this way, even the innermost part of the tumor is supplied with nutrients.
Curbing blood vessel formation as a treatment for cancer
Peter Carmeliet and his colleagues are using this knowledge concerning the formation of blood vessels, or angiogenesis, to develop new therapies for cancer. Indeed, when the formation of blood vessels that feed tumor cells is blocked, the tumor starves due to the lack of oxygen and nutrients. The existing anti-angiogenesis drugs eliminate the most important angiogenetic growth factor. Unfortunately, this treatment induces side effects, and in addition the cancer compensates by producing other growth factors, so that the drug loses it effect. Therefore, new anti-angiogenesis treatments are needed urgently.
For several years now, the VIB researchers have been investigating a new angiogenetic growth factor: the placental growth factor, or PLGF. Oddly enough, PLGF only stimulates blood vessel formation in cancer and other diseases, but not in a fetus, young children or pregnant women.
New cancer therapy?
VIB researcher Christian Fischer and his colleagues - under the direction of Peter Carmeliet and in close collaboration with the biotech company ThromboGenics directed by Désiré Collen - have been studying the therapeutic possibilities of anti-PLGF, which retards the action of PLGF. Anti-PLGF not only increases the effectiveness of chemotherapy and the current anti-angiogenesis therapy, but it also inhibits the growth and metastasis of tumors that are resistant to existing drugs. In contrast to the current therapies, anti-PLGF does not trigger a ‘rescue operation’ in which other growth factors are produced as compensation. Another very important consideration is that anti-PLGF induces absolutely no side effects.
The favorable evaluation of anti-PLGF as a potential cancer treatment raises hope for a more effective cancer therapy with fewer side effects - which can be used with children and pregnant women, too. Furthermore, new results indicate that anti-PLGF can also be useful for the treatment of diseases of the eye that lead to blindness. ThromboGenics is focusing on the further development of anti-PLGF as a therapy. The company wants to begin the first clinical tests by the end of this year.
Via www.youtube.com/watch?v=_ZEysIhDsok you can find a 3D animation which clearly shows the described research. Ask a high resolution version before November 1st via firstname.lastname@example.org.Funding
This research has been conducted by Christian Fischer and colleagues in Peter Carmeliet’s ‘Functional genomics of cardiovascular and neurovascular biology and disease’ research group in the VIB Department of Transgene Technology and Gene Therapy, K.U.Leuven – under the direction of Désiré Collen, who is also the CEO of ThromboGenics.(For more info, see:
Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine